Your browser doesn't support javascript.
loading
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
Madan, Bella; Ozelo, Margareth C; Raheja, Priyanka; Symington, Emily; Quon, Doris V; Leavitt, Andrew D; Pipe, Steven W; Lowe, Gillian; Kenet, Gili; Reding, Mark T; Mason, Jane; Wang, Michael; von Drygalski, Annette; Klamroth, Robert; Shapiro, Susan; Chambost, Hervé; Dunn, Amy L; Oldenburg, Johannes; Chou, Sheng-Chieh; Peyvandi, Flora; Millar, Carolyn M; Osmond, Dane; Yu, Hua; Dashiell-Aje, Ebony; Robinson, Tara M; Mahlangu, Johnny.
Afiliação
  • Madan B; Centre for Haemostasis and Thrombosis, Guy's and St Thomas' National Health Service Trust, London, United Kingdom. Electronic address: Bella.Madan@gstt.nhs.uk.
  • Ozelo MC; Hemocentro University of Campinas, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
  • Raheja P; Haemophilia Centre, Royal London Hospital, Barts Health National Health Service Trust, London, United Kingdom.
  • Symington E; Haemophilia Centre, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom.
  • Quon DV; Orthopaedic Hemophilia Treatment Center, Los Angeles, California, USA.
  • Leavitt AD; Hemophilia Treatment Center, University of California San Francisco, San Francisco, California, USA.
  • Pipe SW; Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA.
  • Lowe G; West Midlands Adult Haemophilia Comprehensive Care Centre, University Hospitals Birmingham National Health Service Foundation Trust, Birmingham, United Kingdom.
  • Kenet G; The National Hemophilia Center and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel HaShomer, Tel Aviv University, Tel Aviv, Israel.
  • Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, Minnesota, USA.
  • Mason J; Queensland Haemophilia Centre, Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
  • Wang M; Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • von Drygalski A; Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Klamroth R; Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Berlin, Germany; Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany.
  • Shapiro S; Blood Theme Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Oxford National Institute for Health Research Biomedical Research Centre, Oxfor
  • Chambost H; AP-HM, Department of Pediatric Hematology Oncology, Children Hospital La Timone & Aix Marseille University, Institut national de la santé et de la recherche médicale, Institut national de la recherche agronomique, Centre recherche en CardioVasculaire et Nutrition, Marseille, France.
  • Dunn AL; The Division of Hematology, Oncology, and Blood and Marrow Transplantation at Nationwide Children's Hospital and Ohio State University College of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Oldenburg J; Institute of Experimental Haematology and Transfusion Medicine and Center for Rare Diseases, University Hospital Bonn, Bonn, Germany.
  • Chou SC; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Peyvandi F; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico and Fondazione Luigi Villa, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Millar CM; Centre for Haematology, Imperial College London, London, United Kingdom; Imperial College Healthcare National Health Service Trust, London, United Kingdom.
  • Osmond D; BioMarin Pharmaceutical Inc, Novato, California, USA.
  • Yu H; BioMarin Pharmaceutical Inc, Novato, California, USA.
  • Dashiell-Aje E; BioMarin Pharmaceutical Inc, Novato, California, USA.
  • Robinson TM; BioMarin Pharmaceutical Inc, Novato, California, USA.
  • Mahlangu J; Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
J Thromb Haemost ; 22(7): 1880-1893, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38614387
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Fator VIII / Terapia Genética / Hemofilia A / Hemorragia Limite: Adolescent / Adult / Humans / Male / Middle aged Idioma: En Revista: J Thromb Haemost Assunto da revista: HEMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Fator VIII / Terapia Genética / Hemofilia A / Hemorragia Limite: Adolescent / Adult / Humans / Male / Middle aged Idioma: En Revista: J Thromb Haemost Assunto da revista: HEMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article